Selank
A synthetic analog of tuftsin with anxiolytic properties. Selank is studied for its nootropic, anxiolytic, and immune-modulating effects in cognitive neuroscience research.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How Selank Works
Selank (TP-7) is a synthetic hexapeptide derived from tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro extension identical to that of Semax. Its anxiolytic effects stem primarily from enhancement of GABAergic tone without direct binding to the benzodiazepine site — offering anxiolysis without classic benzo risks. It also stabilizes enkephalin degradation, prolonging endogenous opioid-like calming effects.
- Positive allosteric modulation of GABA-A receptor
- Increases chloride channel opening frequency
- Reduces amygdala hyperactivity under stress
- No direct BZ site occupancy — no tolerance mechanism
- Inhibits enkephalin-degrading enzymes (neprilysin, DPP-IV)
- Elevates met-enkephalin in striatum and cortex
- Produces opioid-mediated anxiolytic effects
- No mu-opioid receptor dependence or withdrawal
- Upregulates BDNF and NGF like Semax
- Supports hippocampal neuroplasticity under chronic stress
- Reduces glucocorticoid-induced hippocampal damage
- Nootropic effects likely mediated via BDNF/TrkB
Selank increases GABA-A receptor function via an allosteric mechanism distinct from benzodiazepines — potentiating chloride ion conductance without requiring occupancy of the BZ site. Simultaneously, it inhibits enkephalin-degrading enzymes (enkephalinase), raising levels of endogenous met- and leu-enkephalin. This dual mechanism produces anxiolysis with low sedation and no physical dependence.
Semenova TP et al., Bull Exp Biol Med (2009): Selank modulates GABA and enkephalin systems in rats.
Preclinical Findings
Research Models
Clinical Data
Clinically Approved Anxiolytic in Russia — Non-Addictive Profile
Selank has been approved for clinical use in Russia for generalized anxiety disorder (GAD) and asthenic states. Phase 2/3 trials demonstrated significant anxiety reduction on standardized scales (HAM-A) with no sedation, psychomotor impairment, or physical dependence even after 4-week courses.
Semenova TP et al., Russian Clinical Psychiatry (2010): Selank in generalized anxiety disorder.
Russian Phase 2/3 clinical trial, GAD patients, n=62
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- No physical dependence or withdrawal syndrome reported in human studies
- No sedation or psychomotor impairment at therapeutic doses
- Approved for clinical use in Russia — significant human safety database
- No hepatotoxic, nephrotoxic, or cardiotoxic signals in preclinical or clinical data
- Intranasal route: minor transient irritation as only commonly reported effect
Selank has regulatory approval in Russia but not in the US, EU, or other major markets. For research use only.
About Selank
A synthetic analog of tuftsin with anxiolytic properties. Selank is studied for its nootropic, anxiolytic, and immune-modulating effects in cognitive neuroscience research.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
